CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

CARTHERA
Advanced Brain Therapy

CARTHERA® is an innovative start-up company with medical devices currently in clinical development

read more

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

June 2017 – CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

Our innovative solutions

CarThera’s medical devices allow for the treatment of brain tumors in outpatient procedures as well as for improvement in the bioavailability of chemotherapeutics

Our Mission

Improve the prognosis of patients with brain tumors through the development of innovative therapeutic ultrasound-based solutions

Our news

June 2017 – CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

SonoCloud®

High Intensity Contact Ultrasound interstitial medical device

An implant that increases the intracerebral penetration of oncology drugs (+400%) by transiently opening the blood-brain barrier (BBB) without increasing dose or subsequent toxicity. The minimally invasive and easy to use SonoCloud® device is also applicable to the treatment of neurodegenerative diseases (e.g. Alzheimer’s).

Read more

 

SonoProbe®

High Intensity Contact Ultrasound interstitial medical device

img2

The only medical device capable of performing biopsy, treatment, and resection of brain tumors in a single, image-guided outpatient procedure, even for complex tumor geometries

The SonoProbe can also be used for the treatment of tumors located in other organs such as the liver or lung

Read more

Home Page
  • unnamed-2
    unnamed-3

     
  • News CarThera

    03.07.2017
    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.

    14.10.2016
    CarThera secures €5.7 million in funding for its DOME project

    October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

    The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.

    15.06.2016
    A world first published in Science Translational Medicine

    SonoCloud® uses ultrasound to achieve permeability of blood vessels in human brain, allowing increased penetration of therapeutic molecules

    Scientific paper published on June 15th 2016 in Science Translational Medicine supports concept of intracranial ultrasound implant developed by CarThera
     
    Research teams from AP-HP hospitals, UPMC University, INSERM laboratories and the ICM incubator performed this breakthrough on brain tumors, paving the way for broader applications in neurological disorders